The Future of Parenteral Nutrition: Key Players, Disease Specific Opportunities and Market Forecasts

Date: October 22, 2010
Pages: 117
Price:
US$ 4,795.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FB2A64B7C99EN
Leaflet:

Download PDF Leaflet

The Future of Parenteral Nutrition: Key Players, Disease Specific Opportunities and Market Forecasts
In 2009, approximately 390,000 patients in the major markets of the US, EU and Canada used parenteral nutrition products, accounting for total product sales of $1.3b. Through 2014, the total number of parenteral nutrition users in will rise by 10.0% per year to 628,000 and sales will expand by 11.3% per year, reflecting only nominal annual price increases. Four manufacturers currently jockey for share in this closely held market: market leader Baxter, enteral and parenteral products suppliers Fresenius Kabi and B. Braun, and Hospira. Although the introduction of new parenteral solutions is infrequent, these four players are differentiating themselves through hardware improvements, expanded pediatric labeling, new product formats and enhanced systems and services for home use. This report investigates these market opportunities, as well as emerging product development trend such as combination products and products developed for specialized disease populations. In each region profiled ?US, Canada and EU ?it investigates near and long term opportunities as well as recent product launches. Finally, it summarizes these opportunities in the context of product development initiatives currently underway at the leading manufacturers.

This report investigates these market opportunities, as well as emerging product development trend such as combination products and products developed for specialized disease populations. In each region profiled – US, Canada and EU – it investigates near and long term opportunities as well as recent product launches. rbcn0013

Scope of this research
  • Develop deeper insight into the size and growth of the US, Canadian and EU parenteral nutrition industry, as well as individual EU country markets.
  • Understand key product development trends in the parenteral nutrition market and the R&D strategies of the major players.
  • Identify short and long term market opportunities in each region.
  • Anticipate future parenteral nutrition market needs in light of the drivers and restraints acting upon the market.
  • Describes the major market drivers and restraints in the US, Canada and EU, with detail provided for Germany, France, UK, Italy, Spain & Poland

Research and analysis highlights

Growth will be driven by increasing usage as the populations in these regions continue to age and incidence of conditions associated with parenteral nutrition, such as cancer and gastrointestinal disease, rises.

The total US, Canadian and EU parenteral nutrition market reached $1.3b in 2009 and is growing by 11.3% per year to reach $2.3bn in 2014. In 2009, Baxter led the market with 29.5% share, followed by Fresenius Kabi with 28.7%, B. Braun Melsungen with 22.2% and Hospira with 16.9%.

Major near term opportunities for new products include improved hardware and accessories, and products developed for home use. Important new recent launches include the triple-chamber bag, which three of the top four manufacturers now offer.

Key reasons to purchase this research
  • What are the regional differences between the parenteral markets in the US, Canada, Germany, France, UK, Italy, Spain and Poland?
  • Which companies are current and future key players and what are the issues driving new product development?
  • What is limiting greater parenteral nutrition usage and how are prescribing decisions made by clinicians?
  • What emerging products could significantly impact parenteral nutrition sales & what new product initiatives are being pursued by the leading players?
  • What will the size and growth of the global parenteral nutrition market be through 2014?
About the author
Disclaimer
Executive summary
Introduction
Parenteral nutrition in the US & Canada
Parenteral nutrition in the EU
Opportunities in parenteral nutrition

CHAPTER 1 INTRODUCTION

Summary
Introduction
Parenteral vs. enteral nutrition
Major disease populations for parenteral nutrition
Cancer patients
Parenteral nutrition for cancer patients
Gastrointestinal disease patients
Parenteral nutrition for GI disease patients
AIDS patients
Parenteral nutrition for AIDS patients
Environments for parenteral nutrition
Inpatient environments
Outpatient environments
Major types of parenteral nutrition & product ingredients
Central vs. peripheral parenteral nutrition
Parenteral vs. total parenteral nutrition (TPN)
Standardized vs. individualized formulas
Pediatric patients
Products and ingredients
Partial parenteral nutrition
Total parenteral nutrition
Opportunities to incorporate medications into products
Alternatives to parenteral nutrition
Market summary
Conclusion

CHAPTER 2 PARENTERAL NUTRITION IN THE US & CANADA

Summary
Introduction
Regulation
Insurance reimbursement
User populations
Parenteral nutrition in the US
Key products and players
Sales and market share, 2009–2014
Sales by disease population
How clinicians select products
New product development
Opportunities
Near term (2010–2012)
Long term (2013–2014)
Parenteral nutrition in Canada
Key products and players
Sales and market share, 2009–2014
Sales by disease population
How clinicians select products
New product development
Opportunities
Near term (2010–2012)
Long term (2013–2014)
Conclusions

CHAPTER 3 PARENTERAL NUTRITION IN THE EU

Summary
Introduction
Regulation
Insurance Reimbursement
User populations
Parenteral nutrition in the EU
Key products and players
Sales and market share
Total sales
Germany
France
UK
Italy
Spain
Poland
Sales by disease population
Germany
France
UK
Italy
Spain
Poland
How clinicians select products
New product development
Opportunities
Near term (2010–2012)
Long term (2013–2014)
Conclusions

CHAPTER 4 OPPORTUNITIES IN PARENTERAL NUTRITION

Summary
Introduction
New products and other opportunities by product
Improved hardware and accessories
Automation
Non-intravenous product formats
Products for selected disease populations
Products designed for home use
Combination products
Pediatric products
Product development strategies of leading parenteral nutrition players
B. Braun
Baxter
Fresenius Kabi
Hospira
Conclusion
Appendix
Scope
Methodology
Primary research
Secondary research
Glossary/Abbreviations
References

TABLE OF FIGURES

Figure 1: Advantages and disadvantages of parenteral nutrition
Figure 2: Major routes of parenteral nutrition
Figure 3: Number of parenteral nutrition patients in the US, Canada & EU, 2009– 14
Figure 4: Sales of parenteral nutrition products ($m), in the US Canada & EU, 2009– 14
Figure 5: Sales of parenteral nutrition products ($m), in the US, Canada and EU by disease population, 2009 - 2014
Figure 6: Sales of parenteral nutrition products ($m), in the US, Canada and EU by major manufacturer, 2009
Figure 7: Number of parenteral nutrition patients in the US and Canada, 2009– 14
Figure 8: US parenteral nutrition market ($m), 2009– 14
Figure 9: Leading US parenteral nutrition players, 2009
Figure 10: US parenteral nutrition market by disease population ($m), 2009– 14
Figure 11: Triple-chamber bag, dual-chamber bag and traditional bag
Figure 12: Canadian parenteral nutrition market ($m), 2009–2014
Figure 13: Leading Canadian parenteral nutrition players, 2009
Figure 14: Canadian parenteral nutrition market ($m), by disease population, 2009– 14
Figure 15: Number of EU parenteral nutrition patients, 2009–14
Figure 16: EU country potential for parenteral nutrition, 2010
Figure 17: Total EU parenteral nutrition market ($m), 2009– 14
Figure 18: Leading EU parenteral nutrition players ($m), 2009
Figure 19: German parenteral nutrition market and patients ($m), 2009– 14
Figure 20: French parenteral nutrition market and patients ($m), 2009– 14
Figure 21: UK parenteral nutrition market and patients ($m), 2009– 14
Figure 22: Italian parenteral nutrition market and patients ($m), 2009– 14
Figure 23: Spanish parenteral nutrition market and patients ($m), 2009– 14
Figure 24: Polish parenteral nutrition market and patients ($m), 2009– 14
Figure 25: EU parenteral nutrition market by disease population ($m), 2009– 14
Figure 26: EU hospital stays vs. home care patients, 1990–2010
Figure 27: Parenteral nutrition opportunities by product type, 2010
Figure 28: TPNstation from Health Robotics, 2010
Figure 29: Strategy and product development activities of leading parenteral nutrition product manufacturers, 2010
Figure 30: Ambix-Active infusion pump from Fresenius Kabi

TABLE OF TABLES

Table 1: Indications and contraindications for enteral and parenteral nutrition
Table 2: Patients using parenteral nutrition by condition, 2010
Table 3: Inpatient care facilities in the US, Canada and EU, 2010
Table 4: Basic adult daily requirements for TPN, 2010
Table 5: Basic adult daily requirements for TPN, 2010 (cont.)
Table 6: Sales of parenteral nutrition products ($m), by region and major manufacturer, 2009
Table 7: CMS reimbursement schedule for parenteral nutrition products and accessories, 2009
Table 8: Leading US parenteral nutrition products, 2010
Table 9: Leading Canadian parenteral nutrition products, 2010
Table 10: Leading EU parenteral nutrition products, 2010
Table 11: Demographic data for EU member countries 2006
Table 12: Healthcare data for EU member countries 2006
Table 13: Malnutrition in the EU by country, 2010
Table 14: Selected disease specific clinical nutrition products, 2010
Skip to top


Ask Your Question

The Future of Parenteral Nutrition: Key Players, Disease Specific Opportunities and Market Forecasts
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: